Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.

Medulloblastoma (MB) is one of the most common primary central nervous system tumors in children. Data is lacking of a large cohort of medulloblastoma patients in China. Also, our knowledge on the sensitivity of different molecular subgroups of MB to adjuvant radiation therapy (RT) or chemotherapy (...

Full description

Bibliographic Details
Main Authors: Zhen-Yu Zhang, Jian Xu, Yong Ren, Kay Ka-Wai Li, Ho-Keung Ng, Ying Mao, Ping Zhong, Yu Yao, Liang-Fu Zhou
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4059646?pdf=render
id doaj-09cb3b2474aa4a03987ab39583ec4ffd
record_format Article
spelling doaj-09cb3b2474aa4a03987ab39583ec4ffd2020-11-25T01:34:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0196e9949010.1371/journal.pone.0099490Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.Zhen-Yu ZhangJian XuYong RenKay Ka-Wai LiHo-Keung NgYing MaoPing ZhongYu YaoLiang-Fu ZhouMedulloblastoma (MB) is one of the most common primary central nervous system tumors in children. Data is lacking of a large cohort of medulloblastoma patients in China. Also, our knowledge on the sensitivity of different molecular subgroups of MB to adjuvant radiation therapy (RT) or chemotherapy (CHT) is still limited. The authors performed a retrospective study of 173 medulloblastoma patients treated at two institutions from 2002 to 2011. Formalin-fixed paraffin embedded (FFPE) tissues were available in all the cases and sections were stained to classify histological and molecular subgroups. Univariate and multivariate analyses were used to investigate prognostic factors. Of 173 patients, there were 118 children and 55 adults, 112 males and 61 females. Estimated 5-year overall survival (OS) rates for all patients, children and adults were 52%, 48% and 63%, respectively. After multivariate analysis, postoperative primary radiation therapy (RT) and chemotherapy (CHT) were revealed as favorable prognostic factors influencing OS and EFS. Postoperative primary chemotherapy (CHT) was found significantly improving the survival of children (p<0.001) while it was not a significant prognostic factor for adult patients. Moreover, patients in WNT subtype had better OS (p = 0.028) than others (SHH and Non-SHH/WNT subtypes) given postoperative adjuvant therapies. Postoperative primary RT was found to be a strong prognostic factor influencing the survival in all histological and molecular subgroups (p<0.001). Postoperative primary CHT was found significantly to influence the survival of classic medulloblastoma (CMB) (OS p<0.001, EFS p<0.001), SHH subgroup (OS p = 0.020, EFS p = 0.049) and WNT subgroup (OS p = 0.003, EFS p = 0.016) but not in desmoplastic/nodular medulloblastoma (DMB) (OS p = 0.361, EFS p = 0.834) and Non-SHH/WNT subgroup (OS p = 0.127, EFS p = 0.055). Our study showed postoperative primary CHT significantly influence the survival of CMB, SHH subgroup and WNT subgroup but not in DMB and Non-SHH/WNT subgroup of MB.http://europepmc.org/articles/PMC4059646?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Zhen-Yu Zhang
Jian Xu
Yong Ren
Kay Ka-Wai Li
Ho-Keung Ng
Ying Mao
Ping Zhong
Yu Yao
Liang-Fu Zhou
spellingShingle Zhen-Yu Zhang
Jian Xu
Yong Ren
Kay Ka-Wai Li
Ho-Keung Ng
Ying Mao
Ping Zhong
Yu Yao
Liang-Fu Zhou
Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
PLoS ONE
author_facet Zhen-Yu Zhang
Jian Xu
Yong Ren
Kay Ka-Wai Li
Ho-Keung Ng
Ying Mao
Ping Zhong
Yu Yao
Liang-Fu Zhou
author_sort Zhen-Yu Zhang
title Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
title_short Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
title_full Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
title_fullStr Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
title_full_unstemmed Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
title_sort medulloblastoma in china: clinicopathologic analyses of shh, wnt, and non-shh/wnt molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Medulloblastoma (MB) is one of the most common primary central nervous system tumors in children. Data is lacking of a large cohort of medulloblastoma patients in China. Also, our knowledge on the sensitivity of different molecular subgroups of MB to adjuvant radiation therapy (RT) or chemotherapy (CHT) is still limited. The authors performed a retrospective study of 173 medulloblastoma patients treated at two institutions from 2002 to 2011. Formalin-fixed paraffin embedded (FFPE) tissues were available in all the cases and sections were stained to classify histological and molecular subgroups. Univariate and multivariate analyses were used to investigate prognostic factors. Of 173 patients, there were 118 children and 55 adults, 112 males and 61 females. Estimated 5-year overall survival (OS) rates for all patients, children and adults were 52%, 48% and 63%, respectively. After multivariate analysis, postoperative primary radiation therapy (RT) and chemotherapy (CHT) were revealed as favorable prognostic factors influencing OS and EFS. Postoperative primary chemotherapy (CHT) was found significantly improving the survival of children (p<0.001) while it was not a significant prognostic factor for adult patients. Moreover, patients in WNT subtype had better OS (p = 0.028) than others (SHH and Non-SHH/WNT subtypes) given postoperative adjuvant therapies. Postoperative primary RT was found to be a strong prognostic factor influencing the survival in all histological and molecular subgroups (p<0.001). Postoperative primary CHT was found significantly to influence the survival of classic medulloblastoma (CMB) (OS p<0.001, EFS p<0.001), SHH subgroup (OS p = 0.020, EFS p = 0.049) and WNT subgroup (OS p = 0.003, EFS p = 0.016) but not in desmoplastic/nodular medulloblastoma (DMB) (OS p = 0.361, EFS p = 0.834) and Non-SHH/WNT subgroup (OS p = 0.127, EFS p = 0.055). Our study showed postoperative primary CHT significantly influence the survival of CMB, SHH subgroup and WNT subgroup but not in DMB and Non-SHH/WNT subgroup of MB.
url http://europepmc.org/articles/PMC4059646?pdf=render
work_keys_str_mv AT zhenyuzhang medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT jianxu medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT yongren medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT kaykawaili medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT hokeungng medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT yingmao medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT pingzhong medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT yuyao medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT liangfuzhou medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
_version_ 1725070730067968000